Login / Signup

Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers.

Max MasthoffPhilipp SchindlerFabian HardersWalter HeindelChristian WilmsHartmut H SchmidtAndreas PascherLars SteggerKambiz RahbarMichael KöhlerMoritz Wildgruber
Published in: Journal of cancer research and clinical oncology (2020)
A substantial number of patients are precluded from TARE following 99mTc-MAA evaluation, which is, therefore, implicitly needed to determine contraindications to TARE and should not be refrained from in pretreatment process. However, a preceding careful patient selection is needed especially in patients with high hepatic tumor burden and alteration in lab parameters.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • case report
  • stem cells
  • risk factors
  • bone marrow
  • young adults
  • liver metastases
  • patient reported